Clinical Trials

NCT Number: NCT05067140 Phase: Phase 1|Phase 2 Trial Summary: A Phase 1/2 study to evaluate the safety and efficacy of ARV-766 given by mouth in men with metastatic castration-resistant prostate cancer who have progressed on prior approved sy – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Arvinas Androgen Receptor, Inc. Acronym:

NCT Number: NCT03972657 Phase: Phase 1|Phase 2 Trial Summary: The primary objectives of the study in Dose Escalation are to evaluate safety, tolerability, and pharmacokinetics (PK) of REGN5678 alone and in combination with cemiplimab and in D – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Regeneron Pharmaceuticals Acronym:

NCT Number: NCT04363164 Phase: Phase 2 Trial Summary: Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Acronym:

NCT Number: NCT04471974 Phase: Phase 2 Trial Summary: This phase II trial investigates how well ZEN-3694, enzalutamide, and pembrolizumab work in treating patients with castration-resistant prostate cancer that has spread to other pla – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Rahul Aggarwal Acronym:

NCT Number: NCT04631744 Phase: Phase 2 Trial Summary: The purpose of this study is to determine what effects (good and bad) cabozantinib has in treatment of patients with metastatic castrate resistant prostate cancer (mCRPC) – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Weill Medical College of Cornell University Acronym:

NCT Number: NCT04662580 Phase: Phase 1 Trial Summary: A Phase 1, Multicenter, Open-label, Dose-escalation, and Dose expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of ARX517 in Subjects with Advanced – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Ambrx, Inc. Acronym: ARX517

NCT Number: NCT04703920 Phase: Phase 1 Trial Summary: This Phase 1 dose-escalation trial is to determine the safety, tolerability and recommended phase 2 dose of talazoparib in combination with belinostat in subjects with Metastatic B – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Michigan Rogel Cancer Center Acronym:

NCT Number: NCT04754191 Phase: Phase 2 Trial Summary: This is an open-label, phase II umbrella trial assessing the anti-tumor activity of enfortumab alone and in combination with other anti-cancer agents in subjects with metastatic ca – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Utah Acronym: ENCORE

NCT Number: NCT04931823 Phase: Phase 1 Trial Summary: This is a Phase 1, multicenter, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor a – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Conjupro Biotherapeutics, Inc. Acronym:

NCT Number: NCT04946370 Phase: Phase 1|Phase 2 Trial Summary: This is a phase I/II study investigating the combination of 225Ac-J591 (a drug that can deliver radiation to prostate cancer cells) with pembrolizumab (immunotherapy, a drug that i – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Weill Medical College of Cornell University Acronym: